Diplomat Pharmacy (NYSE:DPLO) Trading 5.5% Higher

Shares of Diplomat Pharmacy Inc (NYSE:DPLO) traded up 5.5% during trading on Thursday . The stock traded as high as $6.01 and last traded at $5.97. 1,052,182 shares changed hands during trading, a decline of 6% from the average session volume of 1,117,749 shares. The stock had previously closed at $5.66.

Several research analysts have commented on the stock. ValuEngine raised shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Credit Suisse Group cut their target price on shares of Diplomat Pharmacy from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Monday, April 29th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Wells Fargo & Co cut their target price on shares of Diplomat Pharmacy from $16.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, March 19th. Finally, Morgan Stanley cut their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Monday, March 18th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $10.25.

The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.66 and a current ratio of 1.00. The stock has a market cap of $454.98 million, a PE ratio of 30.45 and a beta of 0.82. The company has a fifty day moving average of $5.04.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.26). The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The firm’s revenue for the quarter was down 6.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.01) EPS. On average, sell-side analysts forecast that Diplomat Pharmacy Inc will post -0.53 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans boosted its holdings in Diplomat Pharmacy by 2.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 39,424 shares of the company’s stock valued at $531,000 after acquiring an additional 867 shares in the last quarter. Texas Permanent School Fund boosted its holdings in Diplomat Pharmacy by 4.1% in the fourth quarter. Texas Permanent School Fund now owns 37,039 shares of the company’s stock valued at $499,000 after acquiring an additional 1,458 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Diplomat Pharmacy by 0.8% in the fourth quarter. New York State Common Retirement Fund now owns 216,819 shares of the company’s stock valued at $2,918,000 after acquiring an additional 1,706 shares in the last quarter. BDO Wealth Advisors LLC bought a new stake in Diplomat Pharmacy in the fourth quarter valued at $27,000. Finally, Great West Life Assurance Co. Can boosted its holdings in Diplomat Pharmacy by 8.7% in the fourth quarter. Great West Life Assurance Co. Can now owns 71,458 shares of the company’s stock valued at $886,000 after acquiring an additional 5,702 shares in the last quarter. Institutional investors and hedge funds own 79.45% of the company’s stock.

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: What are municipal bonds?

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.